RxDoctor Payments Data

Dylan Carroll, MD

Internal Medicine · Warner Robins, GANPI 1457814618

Payments from drug & device makers

$975in general payments, 2019–2025

Across 20 payments — averaging $48.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$181
  • Boehringer Ingelheim$130
  • Johnson & Johnson$125
  • GSK$125
  • Alkermes, Inc.$120
  • Idorsia Pharmaceuticals US Inc$118
  • plus $177 from 6 others

What the payments were for

  • Food & beverage$975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$975 in reported general payments places this provider in the 65th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$56,463
Medicare patients
92
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol68$76,247
OzempicSemaglutide41$69,970
JardianceEmpagliflozin75$69,008
MounjaroTirzepatide37$36,975
TrulicityDulaglutide14$12,935
EliquisApixaban11$12,216
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,822
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$6,184
Duloxetine Hcl137$2,705
Rosuvastatin Calcium88$1,258
Bupropion XlBupropion Hcl48$1,132
Metformin Hcl ErMetformin Hcl68$811
Gabapentin54$779
Omeprazole50$737
Colchicine12$671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$181$76,24768 claims
Boehringer IngelheimJardiance, Stiolto Respimat$130$75,19286 claims
Novo NordiskOzempic$82$69,97041 claims
Lilly USA, LLCMounjaro, Trulicity$17$49,91051 claims
GSKTrelegy Ellipta$125$9,82211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →